Previous 10 | Next 10 |
High conviction. That's what you want to have with the stocks you buy. Such stocks are ones that you can be enthusiastic about -- and buy heavily. We asked three Motley Fool contributors to identify stocks for which they have high convictions about buying right now. Here's why they think that...
- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 12:00 pm ET / 9:00 am P...
In seeking the best stocks in healthcare or cannabis under $20, I look for companies that have consistent revenue growth and a business where there's still plenty of untapped potential, considering long-term trends. Two that stand out in these categories now are biotech company Exelix...
— Presentations to be webcast on www.exelixis.com — Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in November: Stifel...
As Thanksgiving approaches, 2022 is coming to a close -- and what a year the stock market had. The S&P 500 is still down 21% year to date. Most growth stocks have taken a beating this year. But amid this downfall, some companies still shone, giving investors a glimpse of hope. O...
Summary Today, we circle back on mid-cap oncology concern Exelixis, Inc. which just delivered another quarter of rock-solid results. Its blockbuster drug CABOMETYX continues to show good growth and the company is sitting on a massive cash hoard. What is the best way to trade t...
— New priority discovery programs focused on three oncology targets with potential to develop antibody-drug conjugates (ADCs) for a variety of solid tumor indications — Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announce...
Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q3 2022 Earnings Call Nov 01, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q3 2022 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Se...
Exelixis ( NASDAQ: EXEL ) has brokered collaboration deals with two companies giving the biotech the right to acquire a potential first-in-class peptide-drug conjugate and work on the development of an antibody targeting SIRPα. In its deal with Cybrexa Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...